RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Myostrain, Cortex's own studies have left a lot to be desired, though some of that was bad luck. AD PET has been a disaster, likewise DARPA's EDS study (trial design problems). The UK Sleep Dep study had its problems, but still yielded some useful data. So far only ADHD has been a clear success (although the trial design left the door open for it to flop completely, luckily it didn't). Now we have RD, and this trial has to be a success, or else.

Concerning Org-24448, this compound provided POC for Schizo (we don't know what the results were though). Org-26576 has replaced it for Depression, and of course the ADHD trial is the big reason to be excited. We still don't know the exact patent life remaining for Org-26576 though -- if it's like the other older compounds (2017), then it's probably viewed by Schering as only proof of concept, so they'll have to partner for Cortex's newer compounds if they want to go toward commercialization.